| Name | Title | Contact Details |
|---|
We arent your typical cookie-cutter insurance agency. We are privately owned and obsessed with serving our customers and our employees to the very best of our ability. We have the know-how to expertly manage risk, assets, and compliance and the grit to get the job done. Our team is made up of the brightest and most hardworking folks in the insurance industry. Were a bunch of misfits taking care of business every day. Let us know how we can take care of you.
Franklin Products, inc. was founded in 1992 to fill a niche in the marketplace for high quality fluid bed dryer exhaust filters at highly competitive price points for the pharmaceutical industry. Successes in the pharmaceutical industry led to rapid growth into other industries such as food production and chemical manufacturing. All markets where the best quality product is required to do the job!
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.